ĐÁNH GIÁ KẾT QUẢ BAN ĐẦU TRONG ĐIỀU TRỊ HÓA CHẤT TÂN BỔ TRỢ PHÁC ĐỒ CÓ BEVACIZUMAB TRÊN BỆNH NHÂN UNG THƯ BIỂU MÔ BUỒNG TRỨNG TẠI BỆNH VIỆN K

Abstract

Objectives: To evaluate the treatment outcomes of neoadjuvant chemotherapy regimens containing Bevacizumab in patients with epithelial ovarian cancer at K Hospital. Patients and method: A combined retrospective–prospective descriptive study was conducted on 53 patients with epithelial ovarian cancer (EOC), stage IIIC–IV, who received neoadjuvant chemotherapy with Bevacizumab at K Hospital from January 2021 to September 2025. Results: The mean age was 57.3 ± 10.3 years (range: 31–73). Patients < 60 years accounted for 52.8%, while those ≥ 60 years accounted for 47.2%. Patients with ECOG performance status = 2 accounted for 34%. The most common presenting symptoms were pelvic pain (83.3%) and peritoneal ascites (75.4%). The most frequent clinical signs were ascites (90.5%) followed by peripheral lymphadenopathy (28.3%). Stage IV disease accounted for 45.2%. High-grade serous carcinoma was the predominant histological type, accounting for 90.5%. The overall response rate was 98.1%, including 9.4% complete responses, with no cases of disease progression. The optimal cytoreduction rate after neoadjuvant therapy was 85%, of which complete cytoreduction (R0) accounted for 56.6%. There were 8 cases (15.1%) in which optimal surgery was not achieved. Among 48 patients with high-grade serous carcinoma, 11.5% achieved a complete pathological response; partial pathological response predominated at 89.5%. A total of 20.8% of patients required blood transfusion. Two out of 53 patients (3.8%) required creation of a stoma. No cases required bowel or organ resection due to tumor invasion. No postoperative bleeding or thromboembolic complications were recorded.